Q3 Earnings Forecast for Genmab A/S Issued By HC Wainwright

Genmab A/S (NASDAQ:GMAB - Free Report) - Analysts at HC Wainwright dropped their Q3 2024 earnings per share (EPS) estimates for Genmab A/S in a report issued on Wednesday, October 16th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.34 per share for the quarter, down from their previous forecast of $0.35. HC Wainwright has a "Buy" rating and a $50.00 price target on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.27 per share. HC Wainwright also issued estimates for Genmab A/S's FY2024 earnings at $1.36 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The firm had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million.

A number of other equities research analysts also recently weighed in on the stock. BTIG Research boosted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the company a "buy" rating in a research report on Thursday, June 27th. Royal Bank of Canada raised Genmab A/S from a "sector perform" rating to an "outperform" rating in a report on Monday, July 15th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. Morgan Stanley restated an "equal weight" rating and set a $31.00 price objective on shares of Genmab A/S in a research note on Wednesday, September 11th. Finally, Truist Financial cut their target price on Genmab A/S from $53.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $45.20.

Genmab A/S Stock Down 0.9 %

GMAB stock traded down $0.20 during trading on Monday, hitting $22.78. 1,586,118 shares of the company's stock traded hands, compared to its average volume of 626,606. The stock has a fifty day moving average price of $25.66 and a two-hundred day moving average price of $27.01. Genmab A/S has a 52 week low of $22.52 and a 52 week high of $32.89. The stock has a market capitalization of $15.06 billion, a price-to-earnings ratio of 18.98, a price-to-earnings-growth ratio of 0.71 and a beta of 0.98.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in GMAB. Capital International Investors increased its stake in shares of Genmab A/S by 7.8% during the first quarter. Capital International Investors now owns 4,373,277 shares of the company's stock valued at $130,805,000 after acquiring an additional 315,355 shares during the period. Renaissance Technologies LLC increased its position in shares of Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock valued at $36,752,000 after purchasing an additional 103,859 shares during the period. DDD Partners LLC bought a new stake in shares of Genmab A/S in the 2nd quarter worth $8,860,000. Cubist Systematic Strategies LLC raised its stake in shares of Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock worth $7,000,000 after buying an additional 145,689 shares in the last quarter. Finally, Ingalls & Snyder LLC lifted its holdings in shares of Genmab A/S by 29.3% in the second quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company's stock valued at $5,772,000 after buying an additional 52,117 shares during the period. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.